{"id":{"repo_id":"nus","oai_identifier":"oai:scholarbank.nus.edu.sg:10635/209758"},"canonical_url":"https://search.dev.ndltd.org/etd/nus/oai:scholarbank.nus.edu.sg:10635/209758","repository":{"repo_id":"nus","name":"National University of Singapore","base_url":"https://scholarbank.nus.edu.sg/oai/request"},"display":{"title":"NANO-PARTICULATE DRUG CARRIERS FOR EFFECTIVE TARGETING AND DRUG DELIVERY TO BLADDER TUMORS","abstract":"Current intravesical chemotherapy for bladder cancer (BC) has limited efficacy due to lack of specificity of drugs/drug carriers for the tumors and the short residence time of the instilled agent in the bladder due to urine voiding. To address these challenges, albumin-based carriers in two forms i.e., native albumin chains (~16nm) and albumin nanoparticles (HNP ~100nm), both conjugated with a peptide (txCD47) that can specifically target the cluster of differentiation 47 surface receptor overexpressed on BC cells were developed. txCD47-functionalized albumin carrier reduced the IC50 of the loaded drug in the carriers by a factor of 5-10 compared to that of the free drug. The preferential targeting of bladder tumor tissue by txCD47-HNP was confirmed in a mouse orthotopic BC model. Treatment of urine samples from four patients with fluorescence-labeled txCD47-HNP resulted in 83-97% fluorescence-positive cells. Finally, glucose-conjugated albumin in presence of hyperthermia enhanced the cytotoxicity of the loaded drug.","abstract_html":"Current intravesical chemotherapy for bladder cancer (BC) has limited efficacy due to lack of specificity of drugs/drug carriers for the tumors and the short residence time of the instilled agent in the bladder due to urine voiding. To address these challenges, albumin-based carriers in two forms i.e., native albumin chains (~16nm) and albumin nanoparticles (HNP ~100nm), both conjugated with a peptide (txCD47) that can specifically target the cluster of differentiation 47 surface receptor overexpressed on BC cells were developed. txCD47-functionalized albumin carrier reduced the IC50 of the loaded drug in the carriers by a factor of 5-10 compared to that of the free drug. The preferential targeting of bladder tumor tissue by txCD47-HNP was confirmed in a mouse orthotopic BC model. Treatment of urine samples from four patients with fluorescence-labeled txCD47-HNP resulted in 83-97% fluorescence-positive cells. Finally, glucose-conjugated albumin in presence of hyperthermia enhanced the cytotoxicity of the loaded drug.","abstract_has_math":false,"creators":["MULLAPUDI SNEHA SREE"],"institution":null,"degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2021,"date_issued":"2021-07-31","date_published":"2021-07-31","updated_at":"2026-07-24T03:31:26Z","subjects":["CD47 targeting, intravesical chemotherapy, targeted therapy, albumin carrier, bladder cancer, urine cytology"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":null,"outbound_label":null,"outbound_source":null},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:creator","label":"Author","values":["MULLAPUDI SNEHA SREE"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.issued","label":"Date","values":["2021-07-31"]},{"key":"dc:relation.isreferencedby","label":"Dc Relation Isreferencedby","values":["https://scholarbank.nus.edu.sg/handle/10635/209758"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["CD47 targeting, intravesical chemotherapy, targeted therapy, albumin carrier, bladder cancer, urine cytology"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://scholarbank.nus.edu.sg/bitstreams/b5ba78ba-f268-46ce-95ae-a0a17d92c9de/download"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Current intravesical chemotherapy for bladder cancer (BC) has limited efficacy due to lack of specificity of drugs/drug carriers for the tumors and the short residence time of the instilled agent in the bladder due to urine voiding. To address these challenges, albumin-based carriers in two forms i.e., native albumin chains (~16nm) and albumin nanoparticles (HNP ~100nm), both conjugated with a peptide (txCD47) that can specifically target the cluster of differentiation 47 surface receptor overexpressed on BC cells were developed. txCD47-functionalized albumin carrier reduced the IC50 of the loaded drug in the carriers by a factor of 5-10 compared to that of the free drug. The preferential targeting of bladder tumor tissue by txCD47-HNP was confirmed in a mouse orthotopic BC model. Treatment of urine samples from four patients with fluorescence-labeled txCD47-HNP resulted in 83-97% fluorescence-positive cells. Finally, glucose-conjugated albumin in presence of hyperthermia enhanced the cytotoxicity of the loaded drug."]},{"key":"dc:format.checksum.md5","label":"Dc Format Checksum Md5","values":["b6527b5a782794cf9d41f58b0bedd069","8459478811ea69511c028aaf8514c821"]},{"key":"dc:title","label":"Title","values":["NANO-PARTICULATE DRUG CARRIERS FOR EFFECTIVE TARGETING AND DRUG DELIVERY TO BLADDER TUMORS"]}]}],"canonical_facts":{"dc:creator":["MULLAPUDI SNEHA SREE"],"dc:date.issued":["2021-07-31"],"dc:description.abstract":["Current intravesical chemotherapy for bladder cancer (BC) has limited efficacy due to lack of specificity of drugs/drug carriers for the tumors and the short residence time of the instilled agent in the bladder due to urine voiding. To address these challenges, albumin-based carriers in two forms i.e., native albumin chains (~16nm) and albumin nanoparticles (HNP ~100nm), both conjugated with a peptide (txCD47) that can specifically target the cluster of differentiation 47 surface receptor overexpressed on BC cells were developed. txCD47-functionalized albumin carrier reduced the IC50 of the loaded drug in the carriers by a factor of 5-10 compared to that of the free drug. The preferential targeting of bladder tumor tissue by txCD47-HNP was confirmed in a mouse orthotopic BC model. Treatment of urine samples from four patients with fluorescence-labeled txCD47-HNP resulted in 83-97% fluorescence-positive cells. Finally, glucose-conjugated albumin in presence of hyperthermia enhanced the cytotoxicity of the loaded drug."],"dc:format.checksum.md5":["b6527b5a782794cf9d41f58b0bedd069","8459478811ea69511c028aaf8514c821"],"dc:identifier.uri":["https://scholarbank.nus.edu.sg/bitstreams/b5ba78ba-f268-46ce-95ae-a0a17d92c9de/download"],"dc:relation.isreferencedby":["https://scholarbank.nus.edu.sg/handle/10635/209758"],"dc:subject":["CD47 targeting, intravesical chemotherapy, targeted therapy, albumin carrier, bladder cancer, urine cytology"],"dc:title":["NANO-PARTICULATE DRUG CARRIERS FOR EFFECTIVE TARGETING AND DRUG DELIVERY TO BLADDER TUMORS"],"dc:type":["Thesis"]},"updated_at":"2026-07-24T03:31:26Z"}